Cargando…
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
BACKGROUND: Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable. The search for new therapeutic targets is therefore essential. In addition to a wide panel of genetic mutations, epigenetic alterations also appear as important players in the development of this cancer...
Autores principales: | Herviou, Laurie, Ovejero, Sara, Izard, Fanny, Karmous-Gadacha, Ouissem, Gourzones, Claire, Bellanger, Celine, De Smedt, Eva, Ma, Anqi, Vincent, Laure, Cartron, Guillaume, Jin, Jian, De Bruyne, Elke, Grimaud, Charlotte, Julien, Eric, Moreaux, Jérôme |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447659/ https://www.ncbi.nlm.nih.gov/pubmed/34530900 http://dx.doi.org/10.1186/s13148-021-01160-z |
Ejemplares similares
-
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019) -
Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma
por: Devin, Julie, et al.
Publicado: (2022) -
EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015) -
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018) -
Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)